Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials.

IF 2.4 3区医学 Q3 ENDOCRINOLOGY & METABOLISM Journal of Bone and Mineral Metabolism Pub Date : 2024-05-01 Epub Date: 2024-03-27 DOI:10.1007/s00774-024-01500-y

Takuya Wakamatsu, Suguru Yamamoto, Koji Matsuo, Masatomo Taniguchi, Takayuki Hamano, Masafumi Fukagawa, Junichiro James Kazama

{"title":"Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials.","authors":"Takuya Wakamatsu, Suguru Yamamoto, Koji Matsuo, Masatomo Taniguchi, Takayuki Hamano, Masafumi Fukagawa, Junichiro James Kazama","doi":"10.1007/s00774-024-01500-y","DOIUrl":null,"url":null,"abstract":"Introduction: This study aimed to assess the effectiveness of calcimimetics in reducing the risk of fractures in dialysis patients with secondary hyperparathyroidism (SHPT).Material and methods: A comprehensive literature search was conducted using PubMed, Embase, and Cochrane Library for articles published through December 9, 2023. The quality of each trial was evaluated using the Cochrane Collaboration tool. Meta-analysis was performed using a random-effects model, and effect measures across studies were synthesized. The risk ratio (RR) and 95% confidence interval (CI) were used to quantify the risk of fracture.Results: We identified seven studies involving 6481 dialysis patients with SHPT. The administration of calcimimetics reduced fracture incidence compared to placebo or conventional treatment (RR: 0.50, 95% CI 0.29-0.88, p = 0.02). Calcimimetics demonstrated a low number needed to treat (NNT) to prevent an incident fracture (NNT: 47).Conclusion: The use of calcimimetics offers a significant benefit in reducing the risk of fractures in patients undergoing dialysis with SHPT.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"316-325"},"PeriodicalIF":2.4000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Mineral Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00774-024-01500-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This study aimed to assess the effectiveness of calcimimetics in reducing the risk of fractures in dialysis patients with secondary hyperparathyroidism (SHPT).

Material and methods: A comprehensive literature search was conducted using PubMed, Embase, and Cochrane Library for articles published through December 9, 2023. The quality of each trial was evaluated using the Cochrane Collaboration tool. Meta-analysis was performed using a random-effects model, and effect measures across studies were synthesized. The risk ratio (RR) and 95% confidence interval (CI) were used to quantify the risk of fracture.

Results: We identified seven studies involving 6481 dialysis patients with SHPT. The administration of calcimimetics reduced fracture incidence compared to placebo or conventional treatment (RR: 0.50, 95% CI 0.29-0.88, p = 0.02). Calcimimetics demonstrated a low number needed to treat (NNT) to prevent an incident fracture (NNT: 47).

Conclusion: The use of calcimimetics offers a significant benefit in reducing the risk of fractures in patients undergoing dialysis with SHPT.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

降钙药对继发性甲状旁腺功能亢进症透析患者骨折的疗效：随机试验荟萃分析。

简介本研究旨在评估降钙药在降低继发性甲状旁腺功能亢进症（SHPT）透析患者骨折风险方面的有效性：通过PubMed、Embase和Cochrane图书馆对2023年12月9日之前发表的文章进行了全面的文献检索。使用 Cochrane 协作工具对每项试验的质量进行了评估。采用随机效应模型进行了 Meta 分析，并对各项研究的效应量进行了综合。风险比（RR）和 95% 置信区间（CI）用于量化骨折风险：我们确定了七项研究，涉及 6481 名患有 SHPT 的透析患者。与安慰剂或常规治疗相比，服用降钙药可降低骨折发生率（RR：0.50，95% CI 0.29-0.88，P = 0.02）。降钙药的治疗需要量（NNT）较低（NNT：47），可有效预防骨折的发生：结论：使用降钙药可显著降低接受透析治疗的 SHPT 患者的骨折风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Bone and Mineral Metabolism 医学-内分泌学与代谢

CiteScore

6.30

自引率

3.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Bone and Mineral Metabolism (JBMM) provides an international forum for researchers and clinicians to present and discuss topics relevant to bone, teeth, and mineral metabolism, as well as joint and musculoskeletal disorders. The journal welcomes the submission of manuscripts from any country. Membership in the society is not a prerequisite for submission. Acceptance is based on the originality, significance, and validity of the material presented. The journal is aimed at researchers and clinicians dedicated to improvements in research, development, and patient-care in the fields of bone and mineral metabolism.